Fluidic Analytics Limited, a University of Cambridge spinout developing protein characterization technologies, recently raised £5.3m (US$7m) in Series B financing.
The round was led by IQ Capital Partners with participation from the Cambridge Enterprise Seed Fund, Parkwalk Advisors, Draper Esprit, Amadeus Capital Partners and Cambridge Innovation Capital. In conjunction with the funding, Max Bautin joined the Board representing IQ Capital Partners.
The company will use the proceeds to advance its line of laboratory research tools, which are designed to address the key market segments of protein quantitation, quantitative immunoassays and protein-protein interactions.
Led by CEO Andrew Lynn, Fluidic Analytics is developing products based on a new technology for protein characterization that emerged from the laboratory of Professor Tuomas Knowles at the University of Cambridge. The technology allows proteins to be characterized in a rapid, accurate and cost-effective manner.
The company is bringing products to market for applications initially in the research tools market, then in clinical diagnostics and, ultimately, in consumer healthcare.